HRP20211291T1 - Kombinacije i njihove primjene - Google Patents
Kombinacije i njihove primjene Download PDFInfo
- Publication number
- HRP20211291T1 HRP20211291T1 HRP20211291TT HRP20211291T HRP20211291T1 HR P20211291 T1 HRP20211291 T1 HR P20211291T1 HR P20211291T T HRP20211291T T HR P20211291TT HR P20211291 T HRP20211291 T HR P20211291T HR P20211291 T1 HRP20211291 T1 HR P20211291T1
- Authority
- HR
- Croatia
- Prior art keywords
- lymphoma
- synergistic combination
- use according
- hodgkin
- seq
- Prior art date
Links
- 239000011885 synergistic combination Substances 0.000 claims 22
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 9
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 9
- 229960003445 idelalisib Drugs 0.000 claims 9
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Claims (22)
1. Sinergistička kombinacija, naznačena time, da sadrži protutijelo specifično za CD19, pri čemu navedeno protutijelo sadrži regiju HCDR1 sa slijedom SYVMH (SEQ ID NO: 1), regiju HCDR2 sa slijedom NPYNDG (SEQ ID NO: 2), regiju HCDR3 sa slijedom GTYYYGTRVFDY (SEQ ID NO: 3), regiju LCDR1 sa slijedom RSSKSLQNVNGNTYLY (SEQ ID NO: 4), regiju LCDR2 sa slijedom RMSNLNS (SEQ ID NO: 5), i regiju LCDR3 sa slijedom MQHLEYPIT (SEQ ID NO: 6) i Idelalisib za uporabu u liječenju ne-Hodgkinovog limfoma, kronične limfocitne leukemije i/ili akutne limfoblastične leukemije.
2. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 1, naznačena time, da protutijelo sadrži varijabilni teški lanac sa slijedom EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY
NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYW
GQGTLVTVSS (SEQ ID NO: 10) i varijabilni laki lanac sa slijedom
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR
MSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK
(SEQ ID NO: 11).
3. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da protutijelo sadrži konstantnu domenu teškog lanca sa slijedom
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
LLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQV
YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFL
YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).
4. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da protutijelo sadrži konstantnu domenu lakog lanca sa slijedom
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).
5. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib formuliraju u različitim farmaceutskim pripravcima.
6. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib primjenjuju odvojeno.
7. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 6, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib primjenjuju fizički odvojeno.
8. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 6, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib primjenjuju vremenski odvojeno.
9. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib primjenjuju zajedno.
10. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da se Idelalisib primjenjuje prije davanja protutijela koje je specifično za CD19.
11. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da se Idelalisib primjenjuje nakon davanja protutijela koje je specifično za CD19.
12. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da se navedeno protutijelo koje je specifično za CD19 i Idelalisib primjenjuju istovremeno.
13. Sinergistička kombinacija za uporabu u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da se radi o liječenju ne-Hodgkinovog limfoma, pri čemu se opcionalno ne-Hodgkinov limfom bira iz skupine koja se sastoji od folikularnog limfoma, limfoma malih limfocita, limfoma limfnog tkiva vezanog uz sluznicu, limfoma marginalne zone, difuznog limfoma B velikih stanica, Burkittovog limfoma i limfoma plaštenih stanica.
14. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest folikularni limfom.
15. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest limfom malih limfocita.
16. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest limfom limfnog tkiva vezanog uz sluznicu.
17. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest limfom marginalne zone.
18. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest difuzni limfom B velikih stanica.
19. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest Burkittov limfom.
20. Sinergistička kombinacija za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da ne-Hodgkinov limfom jest limfom plaštenih stanica.
21. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačena time, da se radi o liječenju kronične limfocitne leukemije.
22. Sinergistička kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačena time, da se radi o liječenju akutne limfoblastične leukemije.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15181925 | 2015-08-21 | ||
EP16756997.9A EP3337506B1 (en) | 2015-08-21 | 2016-08-18 | Combinations and uses thereof |
PCT/EP2016/069571 WO2017032679A1 (en) | 2015-08-21 | 2016-08-18 | Combinations and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211291T1 true HRP20211291T1 (hr) | 2021-12-10 |
Family
ID=54010888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211291TT HRP20211291T1 (hr) | 2015-08-21 | 2021-08-11 | Kombinacije i njihove primjene |
Country Status (24)
Country | Link |
---|---|
US (2) | US11224654B2 (hr) |
EP (2) | EP3337506B1 (hr) |
JP (3) | JP6862422B2 (hr) |
KR (2) | KR20180042335A (hr) |
CN (2) | CN107921129B (hr) |
AU (3) | AU2016311136B2 (hr) |
BR (1) | BR112018003263A2 (hr) |
CA (1) | CA2995738A1 (hr) |
CY (1) | CY1124706T1 (hr) |
DK (1) | DK3337506T3 (hr) |
ES (1) | ES2891336T3 (hr) |
HK (1) | HK1247122A1 (hr) |
HR (1) | HRP20211291T1 (hr) |
HU (1) | HUE056408T2 (hr) |
IL (2) | IL297057A (hr) |
LT (1) | LT3337506T (hr) |
MX (2) | MX2018002241A (hr) |
PL (1) | PL3337506T3 (hr) |
PT (1) | PT3337506T (hr) |
RS (1) | RS62260B1 (hr) |
RU (1) | RU2767063C2 (hr) |
SI (1) | SI3337506T1 (hr) |
WO (1) | WO2017032679A1 (hr) |
ZA (1) | ZA201801052B (hr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018276384A1 (en) | 2017-05-31 | 2019-11-07 | Incyte Corporation | Treatment paradigm for an anti-CD19 antibody and venetoclax combination treatment |
US11634488B2 (en) | 2017-07-10 | 2023-04-25 | International—Drug—Development—Biotech | Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics |
KR20200030337A (ko) * | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
CA3203587A1 (en) * | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
SI2223922T1 (sl) | 2000-04-25 | 2016-04-29 | Icos Corporation | Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme |
WO2002022212A2 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
US20080152649A1 (en) * | 2002-03-01 | 2008-06-26 | Xencor, Inc. | Optimized igf-1r antibodies and methods of using the same |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
HUE030950T2 (en) | 2004-05-13 | 2017-06-28 | Icos Corp | Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol |
EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
EP2270050B1 (en) | 2005-12-30 | 2013-06-05 | Merck Patent GmbH | Anti-CD19 antibodies with reduced immunogenicity |
ES2402591T3 (es) * | 2006-08-14 | 2013-05-07 | Xencor Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
EP2066349B1 (en) | 2006-09-08 | 2012-03-28 | MedImmune, LLC | Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases |
EP2708557A1 (en) | 2007-05-30 | 2014-03-19 | Xencor, Inc. | Method and compositions for inhibiting CD32B expressing cells |
LT2211904T (lt) | 2007-10-19 | 2016-11-25 | Seattle Genetics, Inc. | Cd19 surišantys agentai ir jų panaudojimas |
US8679492B2 (en) | 2009-02-23 | 2014-03-25 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to CD19 and their uses |
WO2010151341A1 (en) | 2009-06-24 | 2010-12-29 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
DK2493503T4 (da) * | 2009-10-27 | 2021-04-12 | Amgen Res Munich Gmbh | Doseringsplan for administrering af et cd19xcd3-bispecifikt antistof |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
EP2629801B3 (en) * | 2010-10-22 | 2019-11-27 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
KR20200058583A (ko) | 2011-08-16 | 2020-05-27 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
HUE058855T2 (hu) | 2011-08-16 | 2022-09-28 | Morphosys Ag | Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával |
PE20141792A1 (es) | 2012-03-05 | 2014-12-07 | Gilead Calistoga Llc | Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona |
US9808753B2 (en) | 2013-02-15 | 2017-11-07 | 3M Innovative Properties Company | System and method for making pleated filter media |
-
2016
- 2016-08-18 WO PCT/EP2016/069571 patent/WO2017032679A1/en active Application Filing
- 2016-08-18 CN CN201680048061.2A patent/CN107921129B/zh active Active
- 2016-08-18 ES ES16756997T patent/ES2891336T3/es active Active
- 2016-08-18 EP EP16756997.9A patent/EP3337506B1/en active Active
- 2016-08-18 CA CA2995738A patent/CA2995738A1/en active Pending
- 2016-08-18 RU RU2018107929A patent/RU2767063C2/ru active
- 2016-08-18 RS RS20211009A patent/RS62260B1/sr unknown
- 2016-08-18 CN CN202210502807.XA patent/CN115054697B/zh active Active
- 2016-08-18 IL IL297057A patent/IL297057A/en unknown
- 2016-08-18 PL PL16756997T patent/PL3337506T3/pl unknown
- 2016-08-18 JP JP2018508728A patent/JP6862422B2/ja active Active
- 2016-08-18 US US15/752,009 patent/US11224654B2/en active Active
- 2016-08-18 KR KR1020187007728A patent/KR20180042335A/ko not_active Application Discontinuation
- 2016-08-18 BR BR112018003263A patent/BR112018003263A2/pt active Search and Examination
- 2016-08-18 KR KR1020247011695A patent/KR20240052084A/ko not_active Application Discontinuation
- 2016-08-18 MX MX2018002241A patent/MX2018002241A/es unknown
- 2016-08-18 EP EP21186316.2A patent/EP3954388A1/en active Pending
- 2016-08-18 AU AU2016311136A patent/AU2016311136B2/en active Active
- 2016-08-18 LT LTEPPCT/EP2016/069571T patent/LT3337506T/lt unknown
- 2016-08-18 IL IL257345A patent/IL257345B2/en unknown
- 2016-08-18 SI SI201631293T patent/SI3337506T1/sl unknown
- 2016-08-18 DK DK16756997.9T patent/DK3337506T3/da active
- 2016-08-18 HU HUE16756997A patent/HUE056408T2/hu unknown
- 2016-08-18 PT PT167569979T patent/PT3337506T/pt unknown
-
2018
- 2018-02-15 ZA ZA2018/01052A patent/ZA201801052B/en unknown
- 2018-02-20 MX MX2022006154A patent/MX2022006154A/es unknown
- 2018-05-25 HK HK18106849.0A patent/HK1247122A1/zh unknown
-
2021
- 2021-03-31 JP JP2021059383A patent/JP2021113194A/ja active Pending
- 2021-08-11 HR HRP20211291TT patent/HRP20211291T1/hr unknown
- 2021-09-17 CY CY20211100817T patent/CY1124706T1/el unknown
- 2021-12-08 US US17/545,274 patent/US20220088197A1/en active Pending
-
2022
- 2022-04-28 AU AU2022202800A patent/AU2022202800B2/en active Active
-
2023
- 2023-03-30 JP JP2023054891A patent/JP2023093495A/ja active Pending
-
2024
- 2024-04-02 AU AU2024202109A patent/AU2024202109A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192100T1 (hr) | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe | |
HRP20211291T1 (hr) | Kombinacije i njihove primjene | |
HRP20210838T1 (hr) | Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe | |
PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
HRP20220224T1 (hr) | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
JP2017048208A5 (hr) | ||
JP2019533682A5 (hr) | ||
FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
HRP20220228T1 (hr) | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom | |
PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
RU2015110981A (ru) | Комбинации и их применение | |
JP2017507954A5 (hr) | ||
RS54655B1 (en) | DOSAGE MODE FOR USE OF CD19XCD3 Bispecific Antibody | |
BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
JP2023093495A5 (hr) | ||
EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody | |
RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
MX2020004411A (es) | Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren. | |
AR092325A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit | |
PE20201494A1 (es) | Anticuerpo anti-pacap | |
WO2017181099A8 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |